Antigen binding molecules and methods of use thereof

Patent metadata

Field	Value
Publication number	US-10501775-B2
Application number	US-201715646817-A
Country	US
Kind code	B2
Filing date	Jul 11, 2017
Priority date	Jul 12, 2016
Publication date	Dec 10, 2019
Grant date	Dec 10, 2019

Abstract

Isolated antigen binding molecules that specifically binds to a molecule comprising an amino acid sequence selected from the group consisting of GSTSGSGKPGSGEGSTKG (SEQ ID NO: 1), GSGKPGSGEG (SEQ ID NO: 2), GKPGSGEG (SEQ ID NO: 3), SGKPGSGE (SEQ ID NO: 499) and KPGSG (SEQ ID NO: 500) are provided. The antigen binding molecules can be used in the methods provided herein.

First claim

What is claimed is:

1. An isolated antigen binding molecule that specifically binds to a molecule comprising an amino acid sequence selected from the group consisting of GSTSGSGKPGSGEGSTKG (SEQ ID NO: 1), GSGKPGSGEG (SEQ ID NO: 2), GKPGSGEG (SEQ ID NO: 3), SGKPGSGE (SEQ ID NO: 499), and KPGSG (SEQ ID NO: 500), wherein the antigen binding molecule comprises
(a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 7;
(b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 8;
(c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 9;
(d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 13;
(e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 14; and
(f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 15.

2. The isolated antigen binding molecule of claim 1 , wherein the antigen binding molecule is selected from the group consisting of an antibody, an scFv, a Fab, a Fab′, a Fv, a F(ab′)2, a dAb, a human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a polyclonal antibody, a recombinant antibody, an IgE antibody, an IgD antibody, an IgM antibody, an IgG1 antibody, an IgG1 antibody having at least one mutation in the hinge region, an IgG2 antibody, an IgG2 antibody having at least one mutation in the hinge region, an IgG3 antibody, an IgG3 antibody having at least one mutation in the hinge region, an IgG4 antibody, and an IgG4 and antibody having at least one mutation in the hinge region.

3. The isolated antigen binding molecule of claim 2 , wherein the antigen binding molecule is a humanized antibody.

4. The isolated antigen binding molecule of claim 1 , comprising
(a) a heavy chain variable region (VH) amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 5; and
(b) a light chain variable region (VL) amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 11.

5. The isolated antigen binding molecule of claim 4 , comprising
(a) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 5; and
(b) a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 11.

6. The isolated antigen binding molecule of claim 1 comprising
(a) a heavy chain comprising an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 6; and
(b) a light chain comprising an amino acid sequence that is 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 12.

7. The isolated antigen binding molecule of claim 6 comprising at least one of
(a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 6; and
(b) a light chain comprising the amino acid sequence of SEQ ID NO: 12.

8. The isolated antigen binding molecule of claim 6 comprising
(a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 6; and
(b) a light chain comprising the amino acid sequence of SEQ ID NO: 12.

9. An isolated antigen binding molecule that specifically binds to a molecule comprising an amino acid sequence selected from the group consisting of GSTSGSGKPGSGEGSTKG (SEQ ID NO: 1), GSGKPGSGEG (SEQ ID NO: 2), GKPGSGEG (SEQ ID NO: 3), SGKPGSGE (SEQ ID NO: 499), and KPGSG (SEQ ID NO: 500), wherein the antigen binding molecule comprises:
(a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 19;
(b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 20;
(c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 21;
(d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 25;
(e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 26; and
(f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 27.

10. The isolated antigen binding molecule of claim 9 , wherein the antigen binding molecule is selected from the group consisting of an antibody, an scFv, a Fab, a Fab′, a Fv, a F(ab′)2, a dAb, a human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a polyclonal antibody, a recombinant antibody, an IgE antibody, an IgD antibody, an IgM antibody, an IgG1 antibody, an IgG1 antibody having at least one mutation in the hinge region, an IgG2 antibody, an IgG2 antibody having at least one mutation in the hinge region, an IgG3 antibody, an IgG3 antibody having at least one mutation in the hinge region, an IgG4 antibody, and an IgG4 and antibody having at least one mutation in the hinge region.

11. The isolated antigen binding molecule of claim 10 , wherein the antigen binding molecule is a humanized antibody.

12. The isolated antigen binding molecule of claim 9 , comprising
(a) a heavy chain variable region (VH) amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 17; and
(b) a light chain variable region (VL) amino acid sequence that is at least about 95% identical to the amino acid sequence of SEQ ID NO: 23.

13. The isolated antigen binding molecule of claim 10 , comprising
(a) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 17; and
(b) a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 23.

14. The isolated antigen binding molecule of claim 13 comprising
(a) a heavy chain comprising an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 18; and
(b) a light chain comprising an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 24.

15. The isolated antigen binding molecule of claim 14 comprising at least one of
(a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 18; and
(b) a light chain comprising the amino acid sequence of SEQ ID NO: 24.

16. The isolated antigen binding molecule of claim 14 comprising
(a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 18; and
(b) a light chain comprising the amino acid sequence of SEQ ID NO: 24.

17. The antigen binding molecule of any of claims 1 - 16 , wherein the antigen binding molecule further comprises a detectable label.

18. The antigen binding molecule of claim 17 , wherein the detectable label is selected from the group consisting of a fluorescent label, a photochromic compound, a proteinaceous fluorescent label, a magnetic label, a radiolabel, and a hapten.

19. The antigen binding molecule of claim 18 , comprising a fluorescent label selected from the group consisting of an Atto dye, an Alexafluor dye, quantum dots, Hydroxycoumarin, Aminocouramin, Methoxycourmarin, Cascade Blue, Pacific Blue, Pacific Orange, Lucifer Yellow, NBD, R-Phycoerythrin (PE), PE-Cy5 conjugates, PE-Cy7 conjugates, Red 613, PerCP, TruRed, FluorX, Fluorescein, BODIPY-FL, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7, TRITC, X-Rhodamine, Lissamine Rhocamine B, Texas Red, Allophycocyanin (APC), APC-Cy7 conjugates, Indo-1, Fluo-3, Fluo-4, DCFH, DHR, SNARF, GFP (Y66H mutation), GFP (Y66F mutation), EBFP, EBFP2, Azurite, GFPuv, T-Sapphire, Cerulean, mCFP, mTurquoise2, ECFP, CyPet, GFP (Y66W mutation), mKeima-Red, TagCFP, AmCyan1, mTFP1, GFP (S65A mutation), Midorishi Cyan, Wild Type GFP, GFP (S65C mutation), TurboGFP, TagGFP, GFP (S65L mutation), Emerald, GFP (S65T mutation), EGFP, Azami Green, ZsGreen1, TagYFP, EYFP, Topaz, Venus, mCitrine, YPet, TurboYFP, ZsYellow1, Kusabira Orange, mOrange, Allophycocyanin (APC), mKO, TurboRFP, tdTomato, TagRFP,

Assignees

• Kite Pharma Inc

Inventors

• Wiltzius Jed
• SIEVERS Stuart
• Perez Garcia Arianne

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/04

  Immunostimulants · CPC title

• C07K2319/33

  fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies · CPC title

• C07K2319/03

  containing a transmembrane segment · CPC title

• C07K2317/626

  Diabody or triabody · CPC title